The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY PAFSC Second Committee to Review Nobelpharma’s Anticancer Drug Streptozocin on Sept. 5
August 26, 2014
-
BUSINESS Latuda Goes on Sale in UK: Sumitomo Dainippon
August 25, 2014
-
BUSINESS Pfizer Japan to Create New Unit for its Innovative Drug Business in December
August 22, 2014
-
ACADEMIA Kyoto University, Astellas Aim to Develop Immunological Disease Cures, 11 Target Molecules Now under Screening
August 21, 2014
-
BUSINESS MTPC, AZ Ink Research Collaboration Deal in Diabetic Nephropathy
August 21, 2014
-
BUSINESS Japan to See Grueling Battle for Free-Price Viagra Generics
August 20, 2014
-
BUSINESS Pfizer Reveals First Doctor Payments amid Delays in Disclosure
August 19, 2014
-
BUSINESS Genzyme Japan Appoints Former Bausch & Lomb Japan President Ashikaga as Its New President
August 18, 2014
-
REGULATORY 148 Blopress Generics OKed, Competition with AGs Likely upon December Listing
August 15, 2014
-
REGULATORY PMDA Will Prosper by Promoting Review Work, Research, and Training Together: Chief Executive
August 13, 2014
-
ORGANIZATION Fair Discussions Necessary for Full Introduction of New Drug Development Premium: Chuikyo Member
August 12, 2014
-
BUSINESS Asahi Kasei Pharma Aims to Achieve Sales Target of 100 Billion Yen in FY2015 Despite Debut of Flivas Generics: President
August 11, 2014
-
BUSINESS Linical Aims to Become “One-Stop” CRO for Global Clinical Trials
August 8, 2014
-
BUSINESS Daiwa Corporate Investment Establishes Venture Capital Firm Specializing in Biopharmaceuticals; Sights Set on Seeds of University Origin
August 7, 2014
-
REGULATORY MHLW to Survey Rate of Generic Drug Use Under High-Cost Healthcare System; Regulatory Reform Council Concerned that System Provides Little Incentive to Use Generics
August 6, 2014
-
ACADEMIA JSH to Adopt Tougher COI Rule after Panel Said Novartis’s Involvement in SIGN Trial Should Have Been Disclosed at Conference
August 5, 2014
-
BUSINESS Development of Antibody Drugs Accelerating in the Field of Asthma; First New Option Could Be Available as Early as 2016
August 5, 2014
-
REGULATORY MHLW to Fund Research Aimed at Obtaining Additional Indications for Intractable and Orphan Diseases for Existing Drugs
August 4, 2014
-
REGULATORY PAFSC First Committee Backs Approval of MSD’s Insomnia Treatment
August 4, 2014
-
REGULATORY Improvement Order Issued to Novartis over Delayed ADR Reporting
August 1, 2014
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…